Previous close | 0.8300 |
Open | 0.7700 |
Bid | 0.7500 |
Ask | 0.9000 |
Strike | 65.00 |
Expiry date | 2025-03-21 |
Day's range | 0.7700 - 0.7700 |
Contract range | N/A |
Volume | |
Open interest | 199 |
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.